Does Fallon Community Health Plan (FCHP) Cover Dupixent?

What Is Dupixent and Why Does Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines central to type 2 inflammatory disease. The FDA has approved it across six distinct conditions, making it one of the most broadly indicated biologics in outpatient medicine. Because its list price sits near $40,000 per year, insurance coverage determines whether most patients can actually access it.

FDA-Approved Indications as of 2025

The FDA has approved dupilumab for the following conditions, each with its own age cutoff and dosing schedule [1]:

• Moderate-to-severe atopic dermatitis in patients aged 6 months and older
• Moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma (age 6 and older)
• Chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults
• Eosinophilic esophagitis (EoE) in patients aged 12 and older weighing at least 40 kg
• Prurigo nodularis in adults
• Inadequately controlled moderate-to-severe COPD with a type 2 inflammatory phenotype (adults)

Each indication carries its own prior authorization criteria. A prescription written for atopic dermatitis will be reviewed under different step-therapy rules than one written for asthma. Confirming the exact indication on the PA request is the single most common clerical error that leads to initial denials.

The Clinical Evidence Behind the Approvals

Insurance coverage decisions follow FDA labeling, and FDA labeling follows clinical trial data. The key SOLO 1 and SOLO 2 trials (combined N=1,379) showed that dupilumab 300 mg every two weeks produced an IGA 0/1 response in 36-38% of patients at 16 weeks versus 8-10% for placebo (P<0.001) in moderate-to-severe atopic dermatitis [2]. The LIBERTY ASTHMA QUEST trial (N=1,902) demonstrated a 47.7% reduction in severe asthma exacerbations with dupilumab 200 mg every two weeks compared to placebo in patients with baseline blood eosinophils of at least 300 cells/µL [3].

These effect sizes are large enough that most commercial insurers, including FCHP, have placed dupilumab on their specialty tier rather than excluding it outright.

How Fallon Community Health Plan Structures Specialty Drug Coverage

FCHP is a Massachusetts-based not-for-profit health plan serving commercial, Medicare, and Medicaid members across central and eastern Massachusetts. Specialty biologics like dupilumab are managed through the specialty pharmacy tier, which means they require prior authorization, are dispensed through a contracted specialty pharmacy, and may carry higher cost-sharing than standard medications.

Formulary Placement and Tier Structure

FCHP uses a tiered formulary. Dupixent consistently appears on the specialty tier across FCHP commercial plan designs. Specialty tier drugs carry the highest cost-sharing, often a percentage-based coinsurance (typically 20-30%) rather than a flat copay, before the out-of-pocket maximum is reached.

FCHP plan documents are filed annually with the Massachusetts Division of Insurance. Members should download the current Summary of Benefits and Coverage (SBC) and the Drug List (formulary) for their specific plan year directly from the FCHP member portal or request them by calling the member services number on the back of their insurance card. Formulary placement can change between January 1 plan renewals [4].

Prior Authorization Requirements

All FCHP plans require prior authorization for Dupixent. The PA request must document:

1. The specific FDA-approved diagnosis (ICD-10 code required)
2. Disease severity meeting the labeled threshold (e.g., moderate-to-severe for atopic dermatitis)
3. Documented trial and failure of, or contraindication to, first-line therapies
4. Prescriber specialty (dermatology, allergy/immunology, or pulmonology preferred for most indications)
5. Patient age and weight (relevant for pediatric and EoE indications)

For atopic dermatitis specifically, FCHP typically requires documentation of an adequate trial of a medium-to-high potency topical corticosteroid for at least 4 weeks, consistent with the American Academy of Dermatology's Atopic Dermatitis Guidelines [5]. Some plan variants also require a trial of a topical calcineurin inhibitor such as tacrolimus or pimecrolimus.

Step Therapy for Asthma Indications

Asthma prior authorization under most FCHP plans follows the GINA (Global Initiative for Asthma) stepwise framework. Before approving dupilumab for asthma, FCHP generally requires documentation of: uncontrolled symptoms on at least a medium-dose inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA), a baseline blood eosinophil count (typically 150-300 cells/µL depending on plan year), and, for the oral corticosteroid-dependent phenotype, documented OCS use for at least 6 months [3].

The GINA 2024 report states that add-on biologic therapy should be considered for patients remaining uncontrolled at GINA Step 5 despite optimized inhaler therapy [6]. Providing this language directly to the FCHP PA reviewer, along with a copy of the patient's most recent spirometry and eosinophil result, meaningfully shortens review time.

Step Therapy and the Massachusetts Step Therapy Reform Law

Massachusetts enacted step therapy reform legislation that provides protections for patients whose insurer requires them to try-and-fail medications before accessing a prescribed biologic. Under Massachusetts General Law and associated regulations, health plans must grant an exception to step therapy requirements if [7]:

• The required medication is contraindicated for the patient
• The patient previously tried and failed the required drug at any point in their treatment history
• The required drug causes an adverse reaction or clinical harm
• The step therapy delay would cause serious harm

This is significant for FCHP members. A patient who failed topical steroids years before enrolling in their current FCHP plan can use that prior failure history to satisfy step therapy, provided the prescriber documents it in the PA request. The documentation does not need to come from an FCHP-contracted provider. Records from any treating physician, including out-of-network providers, satisfy the requirement.

The Three-Document PA Package That Reduces Denials

Based on the structure of FCHP's PA review process and Massachusetts step therapy law, a well-constructed PA submission for dupilumab should include exactly three core documents sent together as a single fax or electronic submission:

1. The completed PA form with ICD-10 diagnosis code, NDC or drug name, dose, and frequency filled in without blanks.
2. A clinical letter from the prescriber (one page maximum) that states diagnosis, disease severity score (EASI, IGA, or ACQ score), prior therapies tried with dates and outcomes, and the clinical reason dupilumab is the appropriate next step. Quoting the AAD guideline [5] or GINA report [6] by name adds credibility reviewers recognize.
3. Supporting lab or clinical records (eosinophil count for asthma/COPD, endoscopy report for EoE, or photos/clinical notes confirming severity for atopic dermatitis).

Submitting these three documents simultaneously, rather than waiting for a denial and then appealing, is the most efficient path to approval.

What FCHP Pays and What You Owe

Cost-sharing for specialty drugs under FCHP plans is governed by the plan's Schedule of Benefits. After prior authorization is approved, the member's financial responsibility depends on whether they have met their deductible and how their plan structures specialty coinsurance.

Deductible Phase

Before the deductible is met, FCHP members may owe the full contracted rate for Dupixent on a two-week supply basis. The contracted rate is lower than the average wholesale price but can still run $2,500-$3,200 per fill depending on plan year and specialty pharmacy contract. For most members, the annual deductible ($1,000-$4,000 for individual commercial plans) would be met within the first one or two fills.

After Deductible: Coinsurance

Once the deductible is met, specialty tier coinsurance of 20-30% applies until the out-of-pocket maximum is reached. On a $3,500 per-fill cost basis, 20% coinsurance equals $700 per fill, or approximately $1,400 per month for the standard every-two-week dosing schedule in atopic dermatitis. The annual out-of-pocket maximum under ACA-compliant plans is capped at $9,450 for individual coverage in 2025 [8].

Out-of-Pocket Maximum Protection

Once the out-of-pocket maximum is reached, the plan pays 100% of covered costs for the remainder of the plan year. A patient starting dupilumab in January and paying $700 per fill in coinsurance would reach the $9,450 cap around mid-year and owe nothing for subsequent fills through December 31.

Copay Assistance and Patient Support Programs

The Dupixent MyWay program, run by Sanofi and Regeneron, offers copay assistance that can reduce out-of-pocket cost to $0 per month for eligible commercially insured patients. The program is not available to patients with federal or state government insurance (Medicare, Medicaid, CHIP, TRICARE), consistent with federal anti-kickback safe harbors [9].

Eligibility and Enrollment

Enrollment is completed at myway.dupixent.com or by calling 1-844-DUPIXENT. Eligibility requirements include:

• Commercial insurance coverage (FCHP qualifies)
• U.S. Residency
• Prescription for an FDA-approved indication
• Income does not affect eligibility for the commercial copay card

Once enrolled, the MyWay card is applied at the specialty pharmacy at time of dispensing. The card covers the patient's coinsurance and copay up to the program's annual maximum benefit (currently up to $13,000 per year for most indications). For most FCHP members, this means $0 per fill for the entire plan year.

Income-Based Patient Assistance

For uninsured patients or those who are commercially insured but still face affordability barriers, Sanofi's Patient Assistance Program provides Dupixent at no cost to qualifying patients with household income below 600% of the federal poverty level [9]. Applications are submitted through the prescribing physician's office or directly through the MyWay program navigator line.

How to Appeal an FCHP Dupixent Denial

Initial denials are common for specialty biologics. They do not mean coverage is unavailable. They mean the submitted documentation did not satisfy the plan's medical necessity criteria as reviewed. A structured appeal reverses a meaningful share of these decisions.

Internal Appeal

FCHP members have the right to file an internal appeal within 180 days of receiving a denial notice, per Massachusetts law and ACA requirements [10]. For urgent medical conditions, an expedited internal appeal must be decided within 72 hours. Standard internal appeals must be decided within 30 days for prospective requests.

The internal appeal submission should include:

• A copy of the denial letter (note the specific reason cited)
• A revised clinical letter addressing each denial reason point by point
• Published clinical guidelines supporting medical necessity (AAD [5], GINA [6], ACG for EoE [11])
• Peer-reviewed literature (the SOLO trials [2], LIBERTY ASTHMA QUEST [3], or the EoE trial published in NEJM [12])
• Any additional supporting records not included in the original PA request

External Appeal and Independent Medical Review

If the internal appeal is denied, Massachusetts law requires that FCHP offer an external independent medical review (IMR) through a state-certified independent review organization (IRO). The IRO's decision is binding on FCHP. Studies examining commercial insurer denials of biologic therapies show that external appeals involving peer-reviewed clinical evidence succeed at higher rates than unaided internal appeals [13].

State Regulatory Complaint

Members may also file a complaint with the Massachusetts Division of Insurance (DOI) if they believe FCHP has improperly denied coverage. The DOI can investigate whether FCHP applied its step therapy criteria lawfully under Massachusetts regulations [7].

Special Situations: Medicare, Medicaid, and FCHP Senior Plans

FCHP offers Medicare Advantage plans branded as FCHP Senior Care Options and related products. Dupixent coverage under Medicare is subject to Part D rules rather than commercial formulary rules.

Medicare Part D and Dupixent

Under Medicare Part D, dupilumab is covered as a self-administered specialty drug. Part D plans are required to cover all or substantially all drugs in six protected classes, but biologics for atopic dermatitis do not fall within the six protected classes (antidepressants, antipsychotics, anticonvulsants, antiretrovirals, immunosuppressants for transplant, and cancer drugs). Part D plans therefore retain formulary discretion [14].

FCHP Medicare members should check their specific plan's Part D formulary. The Extra Help (Low Income Subsidy) program through the Social Security Administration can reduce Part D specialty tier cost-sharing significantly for qualifying members [14].

MassHealth (Medicaid) and Dupixent

MassHealth, Massachusetts' Medicaid program, covers dupilumab for atopic dermatitis and asthma under its pharmacy benefit, subject to PA requirements administered through the MassHealth Drug List. The Dupixent MyWay manufacturer copay card does not apply to MassHealth members, but MassHealth cost-sharing for pharmacy is minimal or zero for most beneficiary categories [15].

Documenting Medical Necessity: What Dermatologists and Allergists Should Know

Prescribers treating FCHP members can reduce PA cycle time by submitting documentation that maps directly to FCHP's published medical necessity criteria. The criteria themselves closely mirror the AAD Atopic Dermatitis Guidelines [5] and the FDA-approved labeling [1].

Severity Scoring That Moves PA Requests Faster

For atopic dermatitis, include a numerical EASI (Eczema Area and Severity Index) score or IGA (Investigator Global Assessment) score in the clinical note. An EASI score above 21 (moderate-to-severe) or IGA of 3 or 4 maps directly to the moderate-to-severe threshold used in the SOLO trials and in FCHP's criteria [2]. Reviewers with a numeric score in front of them process requests faster than when severity is described only in narrative terms.

For asthma, include the most recent ACQ-5 or ACQ-6 score alongside the blood eosinophil count. An ACQ score above 1.5 signals uncontrolled disease and aligns with GINA's threshold for considering biologic add-on therapy [6].

Atopic Dermatitis Comorbidities That Strengthen the Case

Dupixent's mechanism of IL-4/IL-13 blockade addresses the underlying type 2 immune dysregulation driving atopic march conditions. Documenting comorbid asthma, allergic rhinitis, or food allergy alongside the atopic dermatitis diagnosis strengthens the clinical narrative, because it demonstrates the systemic nature of the disease rather than isolated skin involvement. The 2021 JAMA Dermatology report noted that patients with atopic dermatitis and at least one allergic comorbidity represent 60-70% of the moderate-to-severe population [16].

Practical Checklist Before Submitting the FCHP Prior Authorization

Use this checklist to confirm every required element is present before submitting:

• [ ] Correct ICD-10 code for the specific indication (L20.9 for atopic dermatitis, J45.51 for severe persistent asthma, K20.0 for EoE, etc.)
• [ ] Drug name, dose, and frequency match the FDA-approved labeling [1]
• [ ] Documented trial and failure (dates, drug names, outcomes) of required step therapy agents
• [ ] Severity score (EASI, IGA, ACQ, or endoscopy grade for EoE) included in clinical notes
• [ ] Lab results included where required (eosinophil count for asthma, biopsy for EoE)
• [ ] Prescriber NPI and specialty clearly listed
• [ ] FCHP member ID confirmed as the insurance on file at the specialty pharmacy
• [ ] Dupixent MyWay enrollment initiated in parallel with PA submission

Submitting an incomplete PA form is the leading cause of avoidable delays. FCHP's specialty pharmacy partner will typically call to collect missing information, but this adds 3-5 business days to the approval timeline.